Etude de phase IV, milticentrique, randomisee, ouverte, comparant les reactions et la douleur aux sites d'injection apres administrartion sous-cutaneed' interferon beta-1b (Betaferon(RM)) ou interferon beta-1a (Rebif(RM)) pendant la periode de troi mois d'initiation de la therapie chez des patients atteints d'une forme recurrente/remittente de sclerose en plaques. AVANTAGE: Analyse comparative des reactions aux sites d'injection sur venues apres administration de betaferon 25 microg ou rebif 44 microg

Trial Profile

Etude de phase IV, milticentrique, randomisee, ouverte, comparant les reactions et la douleur aux sites d'injection apres administrartion sous-cutaneed' interferon beta-1b (Betaferon(RM)) ou interferon beta-1a (Rebif(RM)) pendant la periode de troi mois d'initiation de la therapie chez des patients atteints d'une forme recurrente/remittente de sclerose en plaques. AVANTAGE: Analyse comparative des reactions aux sites d'injection sur venues apres administration de betaferon 25 microg ou rebif 44 microg

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2013

At a glance

  • Drugs Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms AVANTAGE
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 12 Jan 2012 Company (Bayer Healthcare) added as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Actual end date changed from 1 Dec 2007 to 1 May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top